Machine signal
Active cluster sell — 4 distinct insiders, $2.2M, window ends Sep 23, 2026.
Figures computed from official regulatory filings — .
Analysttarget 27.5 USD (+48%) · consensus 4.33/5 · 2 buy · 1 hold · 0 sell
Ownershipinsiders 4.08% · institutions 51.08% · short 17.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for OMEROS CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys80 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Borges David J. | Exercise | $155.8K | Unusual size | SEC |
| Borges David J. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borges David J. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borges David J. | Sell | $209.5K | SEC |
| Borges David J. | Exercise | $14.7K | SEC |
| Borges David J. | Sell | $209.5K | SEC |
| Borges David J. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borges David J. | Exercise | $19.7K | SEC |
| Cancelmo Peter B | Exercise | $73.5K | SEC |
| Cancelmo Peter B | Sell | $466.1K | SEC |
| Cancelmo Peter B | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cancelmo Peter B | Sell | $463.5K | SEC |
| Cancelmo Peter B | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cancelmo Peter B | Exercise | $73.5K | SEC |
| HANISH ARNOLD Ctrack record | Sell | $94.4K | SEC |
| HANISH ARNOLD Ctrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HANISH ARNOLD Ctrack record | Exercise | $39.5K | SEC |
| HANISH ARNOLD Ctrack record | Sell | $92.6K | SEC |
| HANISH ARNOLD Ctrack record | Exercise | $79.1K | Unusual size | SEC |
| HANISH ARNOLD Ctrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HANISH ARNOLD Ctrack record | Sell | $95.1K | SEC |
| HANISH ARNOLD Ctrack record | Exercise | $110K | Unusual size | SEC |
| HANISH ARNOLD Ctrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borges David J. | Sell | $17.3K | SEC |
| Borges David J. | Exercise | $12K | SEC |